One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage All Access membership.
Explore Editage All Access
Search from 250 M+ research papersSearch from 250 M+ research papers
Open Accesshttps://doi.org/10.1093/annonc/mdz394.029
Copy DOI Journal: Annals of Oncology |  Publication Date: Oct 1, 2019 |
 Citations: 517 |  License type: publisher-specific-oa |
Affiliation: University of California, San Francisco, Helios Klinikum Emil von Behring, University of California, Los Angeles, Bristol-Myers Squibb (United States), National Cancer Center, Yonsei University, Severance Hospital, The Maria Sklodowska-Curie National Research Institute of Oncology, Hôpital Claude Huriez, Centre Eugène Marquis, Kindai University, University of Hong Kong, National Taiwan University Hospital, Clinica Universidad de Navarra, Centro de Investigación Biomédica en Red, Hôpital de la Croix-Rousse, Assistance Publique – Hôpitaux de Paris, Sorbonne Université, National Cancer Centre Singapore, Memorial Sloan Kettering Cancer CenterLBA38_PR - CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)
Sign-in/Register to access full text options 
Free) Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
